Altamira Therapeutics provides the xPhore™ platform, a peptide‑based nanoparticle system that enables efficient delivery of siRNA, mRNA, circRNA, and DNA therapeutics to extra‑hepatic tissues for pharma and biotech partners. It also markets Bentrio®, a preservative‑free nasal spray for allergic rhinitis, and develops CNS treatments for inner‑ear and neurological disorders.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Effective delivery of nucleic acid therapeutics to tissues outside the liver remains a major bottleneck, limiting the clinical potential of siRNA, mRNA, circRNA, and DNA‑based drugs and vaccines. Additionally, there is a need for convenient, drug‑free treatments for allergic rhinitis and for therapies addressing inner‑ear and CNS disorders.
Solution
Altamira Therapeutics (formerly Auris Medical) offers the xPhore™ platform—a peptide‑based nanoparticle system designed for safe, efficient delivery of various nucleic acid payloads to extrahepatic tissues via systemic or local administration. The platform includes specialized variants: OligoPhore™ for siRNA, SemaPhore™ for mRNA, CycloPhore™ for circRNA, and GenePhore™ for DNA, enabling gene silencing, protein replacement, vaccine delivery, and other therapeutic applications. In parallel, the company commercializes Bentrio®, a preservative‑free nasal spray for prophylaxis and treatment of allergic rhinitis, and develops CNS therapeutics targeting vertigo, hearing loss, and other inner‑ear conditions. By combining advanced delivery technology with consumer health products, Altamira aims to broaden the reach of nucleic acid medicines and address unmet needs in allergy and neuro‑otology.
Target Audience
Primary customers include pharmaceutical and biotechnology companies seeking a versatile nucleic acid delivery platform, as well as consumers and healthcare providers looking for non‑prescription allergy relief and clinicians treating inner‑ear and CNS conditions.
Features
- Peptide‑based xPhore™ nanoparticles that exploit leaky vasculature for targeted delivery to solid tumors and inflamed tissues
- Modular platform variants (OligoPhore™, SemaPhore™, CycloPhore™, GenePhore™) supporting siRNA, mRNA, circRNA, and DNA payloads
- Proven in‑vivo efficacy across ~20 disease models with systemic or local dosing routes
- Bentrio® drug‑free, preservative‑free nasal spray for over‑the‑counter protection against allergens and airborne viruses
- CNS pipeline focused on inner‑ear disorders such as vertigo and hearing loss
- Out‑licensing model enabling pharma and biotech partners to access the delivery technology for their own programs